Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:2653-2659
doi: 10.1161/hc4701.099731
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fu, Y.
Right arrow Articles by Armstrong, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fu, Y.
Right arrow Articles by Armstrong, P. W.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Related Collections
Right arrow Acute coronary syndromes
Right arrow Acute myocardial infarction
Right arrow Peripheral vascular disease
Right arrow Fibrinolysis

(Circulation. 2001;104:2653.)
© 2001 American Heart Association, Inc.


Clinical Investigation and Reports

Time to Treatment Influences the Impact of ST-Segment Resolution on One-Year Prognosis

Insights From the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Trial

Yuling Fu, MD; Shaun Goodman, MD; Wei-Ching Chang, PhD; Frans Van de Werf, MD; Christopher B. Granger, MD; Paul W. Armstrong, MD; , for the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Trial Investigators

From the University of Alberta, Edmonton, Alberta, Canada (Y.F., W.-C.C., P.W.A.); the Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (S.G.); Universitaire Ziekenhuizen Leuven, Leuven, Belgium (F.V.d.W.); and Duke Clinical Research Institute, Durham, NC (C.B.G.).

Correspondence to Paul W. Armstrong, MD, Division of Cardiology, Department of Medicine, 2-51 Medical Sciences Bldg, University of Alberta, Edmonton, Alberta, Canada, T6G 2H7. E-mail paul.armstrong{at}ualberta.ca

Background— Early ST resolution after reperfusion is a prognostic indicator in acute myocardial infarction. Little information exists regarding the prognostic utility of ST resolution beyond 4 hours after fibrinolysis. Furthermore, the relation between time to treatment, ST resolution at 24 to 36 hours, and 1-year outcome has not been well studied. Accordingly, we undertook a prospective ECG substudy in the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) trial to examine this.

Methods and Results— Patients (n=13 100) were stratified into 3 ST-resolution categories, based on baseline and 24- to 36-hour ECGs: complete resolution (>=70%) in 6698 (51.1%) patients, partial resolution (30% to 70%) in 4610 (35.2%) patients, and no resolution (<30%) in 1792 (13.7%) patients; 1-year mortality rate was 5.1%, 8.0%, and 9.7%, respectively (P<0.001). Among patients treated <2 hours after symptom onset, 55.6% had complete ST resolution, whereas 52.1% and 43% of patients treated between 2 to 4 hours and 4 to 6 hours, respectively, had complete ST resolution (P<0.001). Within each category of ST resolution, patients treated <2 hours had lower 1-year mortality rates as compared with patients treated between 2 to 4 hours or >4 hours (3.8% versus 5.2% and 6.6%, P=0.002 in complete ST resolution; 5.7% versus 8.4% and 9.9%, P=0.001 in partial ST resolution; 7.1% versus 8.7% and 13%, P=0.006 in no resolution). The extent of ST resolution was closely and inversely correlated with 1-year mortality rates (r=-0.963, P<0.001).

Conclusions— ST resolution at 24 to 36 hours after fibrinolysis is influenced by time to treatment and inversely related to 1-year mortality rates. Time to treatment further differentiates between high- and low-risk patients and further highlights the importance of reducing time delay to initiation of fibrinolysis in acute myocardial infarction.


Key Words: myocardial infarction • fibrinolysis • reperfusion




This article has been cited by other articles:


Home page
Eur Heart JHome page
R. Vijayaraghavan, A. T. Yan, M. Tan, D. H. Fitchett, A. A. Georgescu, Q. Hassan, A. Langer, S. G. Goodman, and for the Canadian Acute Coronary Syndromes Registry
Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction
Eur. Heart J., January 1, 2008; 29(1): 31 - 37.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. W.A. Verheugt, B. J. Gersh, and P. W. Armstrong
Aborted myocardial infarction: a new target for reperfusion therapy
Eur. Heart J., April 2, 2006; 27(8): 901 - 904.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
A. D. Banks and K. Dracup
Factors Associated With Prolonged Prehospital Delay of African Americans With Acute Myocardial Infarction
Am. J. Crit. Care., March 1, 2006; 15(2): 149 - 157.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W.-C. Chang, P. Kaul, Y. Fu, C. M. Westerhout, C. B. Granger, K. W. Mahaffey, L. Wallentin, F. Van de Werf, P. W. Armstrong, and for the ASSENT-3 Investigators
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction
Eur. Heart J., February 2, 2006; 27(4): 419 - 426.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. Huber, R. D. Caterina, S. D. Kristensen, F. W.A. Verheugt, G. Montalescot, L. B. Maestro, F. V. d. Werf, and for the Task Force on Pre-hospital Reperfusion The
Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction
Eur. Heart J., October 1, 2005; 26(19): 2063 - 2074.
[Full Text] [PDF]


Home page
Am J Crit CareHome page
A. G. Rosenfeld, A. Lindauer, and B. G. Darney
Understanding Treatment-Seeking Delay in Women with Acute Myocardial Infarction: Descriptions of Decision-Making Patterns
Am. J. Crit. Care., July 1, 2005; 14(4): 285 - 293.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, S. A. Murphy, A. J. Kirtane, R. P. Giugliano, C. P. Cannon, E. M. Antman, E. Braunwald, and TIMI Study Group
Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with st-segment elevation myocardial infarction
J. Am. Coll. Cardiol., September 1, 2004; 44(5): 980 - 987.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Bjorklund, B. Lindahl, P. Johanson, T. Jernberg, A.-M. Svensson, P. Venge, L. Wallentin, M. Dellborg, and the ASSENT-2 and ASSENT-PLUS study groups
Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction
Eur. Heart J., January 2, 2004; 25(2): 113 - 120.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
K. Wang, R. W. Asinger, and H. J.L. Marriott
ST-Segment Elevation in Conditions Other Than Acute Myocardial Infarction
N. Engl. J. Med., November 27, 2003; 349(22): 2128 - 2135.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. W. Armstrong, G. Wagner, S. G. Goodman, F. Van de Werf, C. Granger, L. Wallentin, Y. Fu, and for the ASSENT 3 Investigators
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction
Eur. Heart J., August 2, 2003; 24(16): 1515 - 1522.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Fisher
Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3
Stroke, June 1, 2003; 34(6): 1539 - 1546.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
E J P Lamfers, T E H Hooghoudt, D P Hertzberger, A Schut, P W J Stolwijk, and F W A Verheugt
Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients' characteristics, and prognosis
Heart, May 1, 2003; 89(5): 496 - 501.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.P. Ottervanger, P. Armstrong, E.S. Barnathan, E. Boersma, J.S. Cooper, E.M. Ohman, S. James, E. Topol, L. Wallentin, M.L. Simoons, et al.
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina: One-Year Survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial
Circulation, January 28, 2003; 107(3): 437 - 442.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. A. Morrow, E. M. Antman, A. Sayah, K. C. Schuhwerk, R. P. Giugliano, J. A. deLemos, M. Waller, S. A. Cohen, D. G. Rosenberg, S. S. Cutler, et al.
Evaluation of the time saved byprehospital initiation of reteplase forST-elevation myocardial infarction: Results of the early retavase-thrombolysisin myocardial infarction (ER-TIMI) 19 trial
J. Am. Coll. Cardiol., July 3, 2002; 40(1): 71 - 77.
[Abstract] [Full Text] [PDF]


Home page
JWatch Emergency Med.Home page
ST-Segment Resolution Predicts Mortality from Acute MI
Journal Watch Emergency Medicine, January 30, 2002; 2002(130): 1 - 1.
[Full Text]


Home page
Journal Watch CardiologyHome page
Time to Treatment Affects ST-Segment Resolution in Acute MI
Journal Watch Cardiology, January 11, 2002; 2002(111): 4 - 4.
[Full Text]


Home page
CirculationHome page
C. M. Gibson
Time Is Myocardium and Time Is Outcomes
Circulation, November 27, 2001; 104(22): 2632 - 2634.
[Full Text] [PDF]